会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NEW CRYSTALLINE FORMS OF CLOPIDOGREL HYDROBROMIDE AND METHODS OF THEIR PREPARATION
    • 氯碳酸氢盐的新型结晶形式及其制备方法
    • WO2005068471A1
    • 2005-07-28
    • PCT/CZ2004/000089
    • 2004-12-21
    • ZENTIVA, A.S.HAJICEK, JosefPIHERA, PavelSTEPANKOVA, Hana
    • HAJICEK, JosefPIHERA, PavelSTEPANKOVA, Hana
    • C07D495/04
    • C07D495/04
    • The invention concerns clopidogrel hydrobromide in the crystalline Form I characterized by an X-ray diffraction pattern with characteristic interplanar distances d of 4.01; 4.39 and 3.17 ú and which is further characterized by bands in the infrared spectra at 1743; 1421; 1237, 760 and 728 cm -1 . Clopidogrel hydrobromide in the crystalline Form II is characterized by an X­ray diffraction pattern with characteristic interplanar distances d of 4.52; 3.83; 3.48 ú, as well as bands in the infrared spectra at 1754; 1436; 1317 and 1223 cm -1 . Crystalline form III is characterized by the following peaks ascertained by X-ray diffraction at 20 positions: 7.796 °; 15.380 °; 18.389 °; 19.369 ° and 23.895 °. The method of preparation of clopidogrel hydrobromide in the crystalline Form I consist in precipitating the clopidogrel base dissolved in toluene with a concentrated solution of hydrobromic acid. The method of preparation of clopidogrel hydrobromide in the crystalline Form II consist in dissolving the clopidogrel base in an organic solvent and precipitating it with a solution of hydrobromic acid in toluene or with gaseous hydrogen bromide. Form III can be used for the preparation of pharmaceutically applicable Form II.
    • 本发明涉及结晶形式I中的氯吡格雷氢溴酸盐,其特征在于具有4.01的特征性面间距离d的X射线衍射图谱; 4.39和3.17ú,其进一步特征在于1743年红外光谱中的谱带; 1421; 结晶形式II中的氯吡格雷氢溴酸盐的特征在于具有4.52的特征性面间距d的X射线衍射图; 3.83; 3.48ú,以及1754年的红外光谱带; 1436; 1317和1223厘米-1。 结晶形式III的特征在于在20个位置通过X射线衍射确定的以下峰:7.796°; 15.380°; 18.389°; 19.369°和23.895°。 结晶形式I中氯吡格雷氢溴酸盐的制备方法是用氢溴酸浓溶液沉淀溶解在甲苯中的氯吡格雷碱。 在晶型II中制备氯吡格雷氢溴酸盐的方法包括将氯吡格雷碱溶解在有机溶剂中,并用氢溴酸在甲苯或与溴化氢气体的溶液中沉淀。 III型可用于制备药学上适用的II型。
    • 9. 发明申请
    • METHOD OF PRODUCING HIGHLY PURE PRASUGREL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
    • 生产高纯度原料的方法及其药学上可接受的盐
    • WO2011057592A1
    • 2011-05-19
    • PCT/CZ2010/000115
    • 2010-11-12
    • ZENTIVA, K.S.STEPANKOVA, HanaKAMINSKA, KaterinaHAJICEK, Josef
    • STEPANKOVA, HanaKAMINSKA, KaterinaHAJICEK, Josef
    • C07D495/04
    • C07D495/04
    • A method for the production of 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]- 4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate of formula (I) or its salts, characterized in that the compound of formula (III) in the form of a salt with an arene sulfonic acid is reacted with the compound of formula (XV), wherein Y means: chlorine, bromine, or an OR 4 group, wherein R 4 means an alkane sulfonic group or arene sulfonic group, in an organic solvent in the presence of an inorganic base or organic base, to give, after addition of an acetylating reagent and organic base to the reaction mixture, the compound of formula (I), which, after addition of a co-solvent, is crystallized from the reaction mixture, and the compound of formula (I) is optionally purified by crystallization and optionally converted to a salt by reaction with an organic or inorganic acid in a suitable solvent. (Formulae (I), (III), (XV)
    • 制备式(I)的5- [2-环丙基-1-(2-氟苯基)-2-氧代乙基] -4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基乙酸酯的方法 (I)化合物或其盐,其特征在于与式(ⅩⅤ)化合物反应呈与磺酰基磺酸盐形式的式(Ⅳ)化合物,其中Y表示:氯,溴或OR 4 基团,其中R 4表示烷基磺酸基或芳烃磺酸基,在有机溶剂中,在无机碱或有机碱的存在下,在反应混合物中加入乙酰化试剂和有机碱后,得到式 (I),其在加入共溶剂之后从反应混合物中结晶,并且式(I)化合物任选地通过结晶进行纯化,并任选地通过与有机或无机酸反应形成盐 合适的溶剂。 (式(I),(III),(XV)